Pharmaceutical Products Inhibitor CAS 936563-96-1 Inhibitors  Anticancer

New API

Ibrutinib (Imbruvica) is a small molecule drug that binds permanently to a protein, Bruton’s tyrosine kinase (BTK), that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia, a form of non-Hodgkin’s lymphoma.

Ibrutinib was created by scientists at Celera Genomics as a tool compound for studying BTK function, then developed by Pharmacyclics up to Phase II, then partnered with Johnson & Johnson. Pharmacyclics was acquired by AbbVie in May 2015, and Abbvie projected global sales of US$1 billion in 2016 and $5 billion in 2020.

Appearance: white powder

Medical uses:

Ibrutinib is used to treat chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, and marginal zone lymphoma

In addition, it is used for chronic lymphocytic leukemia and lymphocyte lymphoma.